Cure­Vac puts lead on­col­o­gy can­di­date on back burn­er and will on­ly move it for­ward in com­bi­na­tion ther­a­pies

Cure­Vac is putting its lead can­cer ther­a­py on ice — for now.

The trans-at­lantic phar­ma with of­fices in Boston, MA and Ger­many put word of the new de­vel­op­ment in its Q3 earn­ings re­port Wednes­day.

In the con­text of our cur­rent strate­gic fo­cus on the de­vel­op­ment of nov­el mR­NA-based can­cer vac­cines, da­ta from the planned proof-of-prin­ci­ple stud­ies and par­al­lel progress in the dis­cov­ery of new tu­mor-spe­cif­ic anti­gens will pro­vide the ba­sis for any po­ten­tial in­te­gra­tion of CV8102 in­to this pri­or­i­ty pro­gram as a strong im­mune-mod­u­la­to­ry ad­junct. Fur­ther clin­i­cal de­vel­op­ment of CV8102 will on­ly be con­sid­ered in com­bi­na­tion with a de­fined mR­NA can­cer vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER